SEARCH:   Advanced

Blood, 15 July 2004, Vol. 104, No. 2, pp. 328-335. Prepublished online as a Blood First Edition Paper on March 25, 2004; DOI 10.1182/blood-2004-01-0002. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0002v1 104/2/328    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Herling, M. Articles by Jones, D. Search for Related Content PubMed PubMed Citation Articles by Herling, M. Articles by Jones, D. Related Collections Neoplasia Oncogenes and Tumor Suppressors Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories Marco Herling, Joseph D. Khoury, LaBaron T. Washington, Madeleine Duvic, Michael J. Keating, and Dan Jones From the Departments of Hematopathology, Dermatology, and Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston. The current World Health Organization (WHO) classification of hematopoietic malignancies defines several types of mature T-cell leukemia including T-cell prolymphocytic leukemia (T-PLL), Sezary syndrome (SS), and T-cell large granular lymphocytic (T-LGL) leukemia. These neoplasms can show overlapping features with each other and with T-cell lymphomas involving peripheral blood (PB). We analyzed the spectrum of clinicopatho-logic features in 102 mature T-cell leukemias and compared them to 10 hepatosplenic T-cell lymphomas that involved PB. T-PLL, defined as a T-cell leukemia showing rapidly rising PB lymphocyte counts, was the only tumor type expressing the oncoprotein TCL1 (71% of cases) and could present with relatively low lymphocyte levels or small tumor cell morphology. SS, defined by accompanying erythrodermic skin disease, was frequently associated with peripheral eosinophilia but could also develop high numbers of prolymphocytes, especially late in the disease course. T-LGL leukemia, defined by accompanying cytopenias or autoimmune phenomena (or both), had the best clinical outcome and generally showed the lowest circulating lymphocyte levels with only a few cases developing marked lymphocytosis. Using the dominant clinical or phenotypic feature, we describe here the degree of overlap among currently recognized WHO categories and identify areas where further clarification is needed. Our results indicate that incorporation of additional criteria, such as TCL1 expression status and hematologic parameters, can assist in a more accurate classification. (Blood. 2004;104:328-335) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: The WHO classification of mature T-cell leukemias Daniel Catovsky, Estella Matutes, Claire Dearden, Nnenna Osuji, Vasantha Brito-Babapulle, Marco Herling, and Dan Jones Blood 2004 104: 2989-2990. [Full Text] [PDF] This article has been cited by other articles: M. Martinez-Gallo, C. Puy, R. Ruiz-Hernandez, J. M. Rodriguez-Arias, M. Bofill, J. F. Nomdedeu, J. C. Cigudosa, J. L. Rodriguez-Sanchez, and O. de la Calle-Martin Severe and recurrent episodes of bronchiolitis obliterans organising pneumonia associated with indolent CD4+ CD8+ T-cell leukaemia Eur. Respir. J., June 1, 2008; 31(6): 1368 - 1372. [Abstract] [Full Text] [PDF] M. Herling, K. A. Patel, M. A. Teitell, M. Konopleva, F. Ravandi, R. Kobayashi, and D. Jones High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia Blood, January 1, 2008; 111(1): 328 - 337. [Abstract] [Full Text] [PDF] G. Despouy, M. Joiner, E. Le Toriellec, R. Weil, and M. H. Stern The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC{theta} and ERK pathways Blood, December 15, 2007; 110(13): 4406 - 4416. [Abstract] [Full Text] [PDF] Y. Sandberg, K.L. Wu, F. Heule, R.R. van den Bos, K.H. Lam, A.W. Langerak, V.H. van der Velden, K. van Lom, and H.B. Beverloo Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach Haematologica, March 1, 2007; 92(3): e34 - e36. [Full Text] [PDF] M. W. Wlodarski, L. P. Gondek, Z. P. Nearman, M. Plasilova, M. Kalaycio, E. D. Hsi, and J. P. Maciejewski Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome Blood, October 15, 2006; 108(8): 2632 - 2641. [Abstract] [Full Text] [PDF] A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis Blood, June 15, 2006; 107(12): 4834 - 4840. [Abstract] [Full Text] [PDF] M. W. Wlodarski, C. O'Keefe, E. C. Howe, A. M. Risitano, A. Rodriguez, I. Warshawsky, T. P. Loughran Jr, and J. P. Maciejewski Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia Blood, October 15, 2005; 106(8): 2769 - 2780. [Abstract] [Full Text] [PDF] D. Catovsky, E. Matutes, C. Dearden, N. Osuji, V. Brito-Babapulle, M. Herling, and D. Jones The WHO classification of mature T-cell leukemias Blood, November 1, 2004; 104(9): 2989 - 2990. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020